The announcement of preliminary financial results, especially revenue figures, is a critical indicator of a company's performance. For Biodexa Pharmaceuticals, reporting £0.38 million in revenue for FY23 provides investors and analysts with a tangible measure of its financial health and operational success. This information is likely to influence investor sentiment positively, assuming the revenue meets or exceeds market expectations. The direct mention of Biodexa Pharmaceuticals and the specificity of the financial data make this news highly relevant and important for investors, contributing to a positive short-term impact on its stock price.